Adia Nutrition rebrands as Adia Med in regenerative medicine shift

ADIA NUTRITION INC

ADIA NUTRITION INC

ADIA

0.00
  • Adia Med rebranded from Adia Nutrition, aligning its corporate identity with regenerative medicine, stem cell therapies, and biologics.
  • The shift supports a strategy aimed at a NASDAQ uplisting, with remaining hurdles centered on shareholder equity and net revenue thresholds.
  • The company reported $637,145 in revenue in the first nine months of 2025, driven by biologics sales and clinic procedures.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adia Med Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202607130900NEWSFILECNPR____20260713_304722_1) on July 13, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.